para-Aminosalicylic acid (PAS) entered clinical use in 1946 as the second exclusive
drug for the treatment of
tuberculosis (TB). While PAS was initially a first-line TB
drug, the introduction of more potent
antitubercular agents relegated PAS to the second-line tier of agents used for the treatment of
drug-resistant
Mycobacterium tuberculosis infections. Despite the long history of PAS usage, an understanding of the molecular and biochemical mechanisms governing the susceptibility and resistance of M.
tuberculosis to this
drug has lagged behind that of most other TB drugs. Herein, we discuss previous studies that demonstrate PAS-mediated disruption of
iron acquisition, as well as recent genetic, biochemical, and metabolomic studies that have revealed that PAS is a
prodrug that ultimately corrupts one-
carbon metabolism through inhibition of the formation of reduced
folate species. We also discuss findings from laboratory and clinical isolates that link alterations in
folate metabolism to PAS resistance. These advancements in our understanding of the basis of the susceptibility and resistance of M.
tuberculosis to PAS will enable the development of novel strategies to revitalize this and other
antimicrobial agents for use in the global effort to eradicate TB.